Who’s acquiring who? Orphan designated drugs M&A activity in the pharmaceutical industry decreased by 23% in Q1 2023
Pharmaceutical Technology
MAY 28, 2023
Analysis of the key themes driving M&A activity reveals that orphan designated drugs accounted for 20 pharmaceutical deals announced in Q1 2023, worth a total value of $50.2bn. The $43bn acquisition of Seagen by Pfizer was the industry’s largest disclosed deal. GlobalData’s New Drug Approvals and Their Contract Manufacture report provides critical insight into the contract manufacturing organization (CMO) industry by analysing relative performance of major CMOs by number of drug
Let's personalize your content